Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Laboratory Biomarker Analysis, Positron Emission Tomography; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 25
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more

Conditions: Vaginal Dysbiosis
Interventions: FB-301, Placebo, Chlorhexidine (0.5%) Vaginal Cleanse, Sham vaginal cleanse (saline); Drug · Other
Lead sponsor: Freya Biosciences ApS; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Wichita, Kansas • Waltham, Massachusetts • Charlotte, North Carolina + 1 more

Conditions: Metabolic Syndrome
Interventions: fulvic acid, Placebo; Dietary Supplement · Other
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Prostate Cancer
Interventions: Degarelix, Doxorubicin, Ketoconazole, Docetaxel, Estramustine; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: LY3074828; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Infertility, Infertility Secondary, Infertility Unexplained, Anovulation, Fertility Disorders, Reproductive Issues
Interventions: Zymot Multi sperm separation device, Density gradient centrifugation; Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post-traumatic Stress Disorder
Interventions: Mifepristone, d-Cycloserine, Placebo-matching Mifepristone, Placebo-matching d-Cycloserine (DCS); Drug
Lead sponsor: Roger K. Pitman, MD; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Health Risk Behaviors, Health Care Services Quality of Care
Interventions: Check Yourself App with Feedback; Behavioral
Lead sponsor: Laura Richardson; Other
Eligibility: 13 Years to 18 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Influenza
Interventions: Blood Draw; Procedure
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo, 0.5 mgTestosterone + 10 mg Buspirone; Drug
Lead sponsor: Emotional Brain NY Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more

Conditions: Pain
Interventions: dexmedetomidine hydrochloride; Drug
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Diabetic Foot Ulcers (DFUs), Venous Leg Ulcers (VLUs), Pressure Ulcers, Surgical Wound Dehiscence (SWD), Chronic Wounds, Undermined and Tunneling Wounds
Interventions: Acellular Porcine-Derived Wound Matrix; Device
Lead sponsor: Reprise Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Coconut Creek, Florida • Tamarac, Florida

Conditions: Ovarian Cancer, Peritoneal Cancer
Interventions: DCVac-L; Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm
Interventions: ASTX029, ASTX727; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma, Adult
Interventions: NovoTTF-200A, Temozolomide, 3D conformal or intensity modulated radiation therapy (IMRT); Device · Drug · Radiation
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Breast Cancer, Brain Metastases, Adult
Interventions: Olaparib, Stereotactic Radiosurgery, Durvalumab, Physicians Choice systemic chemotherapy; Drug · Radiation
Lead sponsor: Colette Shen; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more

Conditions: Endometrial Cancer
Interventions: Metformin, Letrozole, Everolimus; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 6
States / cities: Pensacola, Florida • Voorhees Township, New Jersey • Houston, Texas

Conditions: Cystic Fibrosis
Interventions: novolog insulin, levemir insulin, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 10 Years to 25 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Meningococcal Vaccine
Interventions: Awareness, Education, Empowerment, Accessibility; Other
Lead sponsor: University of Florida; Other
Eligibility: 16 Years to 99 Years
Enrollment: 1,326 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 6
States / cities: Gainesville, Florida

Conditions: Colonoscopy
Interventions: Golytely Oral Solution; Drug
Lead sponsor: VA Connecticut Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: COVID-19, Cancer
Interventions: Hydroxychloroquine, Placebo, Radiation therapy; Drug · Other · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Surgery, Surgical Site Infection, Cutibacterium Acnes, Prosthetic-joint Infection
Interventions: Povidone-Iodine, SURGX Wound Gel; Drug · Device
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cystic Fibrosis
Interventions: Linezolid; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
Interventions: Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle

Fulvic Acid Supplementation and Metabolic Syndrome

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

A Study of LY3074828 in Healthy Participants

Sperm Preparation Prior to Intrauterine Insemination Study

Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments

Check Yourself Study

Immunogenicity of Influenza Vaccine in Long Term Care

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

Safety and Efficacy of Intravenous (IV) Dexmedetomidine During Flexible Bronchoscopy and Endobronchial Ultrasound

Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

MenB Vaccine: Implementation Via Information, Empowerment and Accessibility

Polyethylene Glycol Cleansing in Patients at High Risk for Poor Bowel Preparation

A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy

SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty

Pharmacokinetics of Linezolid in Children With Cystic Fibrosis

Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma